←
Cory Simpson, MD, PhD, FAAD (he/him)1,186 posts
Cory Simpson, MD, PhD, FAAD (he/him) avatar

Cory Simpson, MD, PhD, FAAD (he/him)

@CorySimpsonMD

Physician-scientist @UWMedicine @DermatologyUW focused on advanced microscopy, keratinocyte biology, teledermatology, and genetic/autoimmune blistering disease.

◷ Joined January 2019▧ 114 Photos and videos
Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·23 Oct 2024

Exciting week @SimpsonLabUW @DermatologyUW celebrating🍾our newest paper @JCI_insight (see separate🧵). which uncovered a mechanism that drives the pathology #Grover disease and was reversed using MEK inhibitors. Special thanks to Arti for making an amazing Indian lunch buffet!

Post attachment

New paper from @SimpsonLabUW @DermatologyUW is online @JCI_insight🍾We found ERK hyperactivation disrupts cell-cell adhesion in epidermis, linked this pathway to both drug-induced & spontaneous Grover disease & identified MEK inhibition as a novel therapy: insight.jci.org/articles/vie…

Post attachment
Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·17 Oct 2024

Hope this will finally move the needle for severe drug reactions like SJS & TEN, nightmare consults in #dermatology. No Rx has great evidence to halt skin/mucosal sloughing that can be fatal. JAKi remains to be rigorously tested in patients/RCT but could change standard of care.

UCISkin@UciSkin16 Oct 2024

Spatial proteomics identifies JAKi as treatment for a lethal skin disease | Nature nature.com/articles/s41586-0…

nature avatar
⟳ Cory Simpson, MD, PhD, FAAD (he/him) retweeted
nature@Nature·16 Oct 2024

Nature research paper: Spatial proteomics identifies JAKi as treatment for a lethal skin disease go.nature.com/3A1ld7K

Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·10 Oct 2024

This program has been an outstanding opportunity for networking with peers, receiving grant feedback, learning how to navigate the new PI path, and getting sage career advice from leading physician-scientists. 10/10 highly recommend @the_asci. Consider applying

ASCI@the_asci9 Oct 2024

Early-Faculty Physician-Scientists! Nominations are open for the ASCI Young Physician-Scientist Awards. Award Benefits include access to @JointMeeting, networking and career development opportunities. Deadline: Oct. 23 More info: buff.ly/3XUL9ex

Post attachment
Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·10 Oct 2024

Finally, we reasoned the same mechanism could drive spontaneous Grover disease (ie, not drug-induced). Accordingly, we found ERK hyper-activation in Grover disease lesions and propose MEK inhibitors may be therapeutic for this idiopathic disorder lacking any FDA-approved therapy.

Post attachment
Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·10 Oct 2024

In fact, we found multiple different MEK inhibitors restored cell-cell adhesion despite B-RAF blockade. This was consistent with subsequent clinical trial data in which patients treated w/DUAL inhibitors of both B-RAF and MEK no longer got Grover disease as a side effect.

Post attachment
Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·10 Oct 2024

In keratinocytes, we showed ERK hyperactivation was sufficient to disrupt desmosomes & reduce cohesion, explaining why the epidermis falls apart in Grover disease. Importantly, blocking ERK activation w/an FDA-approved MEK inhibitor (trametinib) rescued keratinocyte cohesion.

Post attachment
Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·10 Oct 2024

We validated these findings in skin biopsies from patients who were treated w/vemurafenib and developed drug-induced Grover disease. These biopsies showed hyper-activation of ERK within lesional epidermis, which correlated with the disruption of cell-cell junctions (desmosomes).

Post attachment
Cory Simpson, MD, PhD, FAAD (he/him) avatar
Cory Simpson, MD, PhD, FAAD (he/him)@CorySimpsonMD·10 Oct 2024

The story starts w/an unexpected side effect of B-RAF inhibitors seen in clinical trials for cancer. Some patients developed a skin blistering disorder called Grover disease, in which keratinocytes lose their connections to one another, leading to splitting of the epidermis.

Post attachment
ASCI avatar
⟳ Cory Simpson, MD, PhD, FAAD (he/him) retweeted
ASCI@the_asci·9 Oct 2024

Early-Faculty Physician-Scientists! Nominations are open for the ASCI Young Physician-Scientist Awards. Award Benefits include access to @JointMeeting, networking and career development opportunities. Deadline: Oct. 23 More info: buff.ly/3XUL9ex

Post attachment